leisure time -WSS

leisure time

author：knowledge 2025-09-28 19:19:12 - browse：37886

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

hotspot

focus

WSS

New details revealed about Purdue's marketing of OxyContin

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Living with Hashimoto's and celiac disease, and med school, too

New definition of a human embryo proposed amid rapid advances

Insurer loopholes limit power of law against surprise medical bills

Scientists uncover potential path to treating deadly childhood tumor

explore

leisure time

focus

Wildfire smoke exposes gaps in outdoor worker protections

Mass General Brigham physicians react to latest merger step

Tori Bowie and the unacceptable rates of Black maternal death

Researchers test human milk's ability to repair gut microbiome

Bright Health sells Medicare Advantage business to Molina

Oral obesity drug from Viking Therapeutics hits key early target

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Study: Black kids more likely to die after surgery than white kids

Medical leaders decry Supreme Court decision on affirmative action

Patient advocates sound warning on FDA proposal on salt intake

explore

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

As Maui death toll rises, number of missing remains unclear

Researchers test human milk's ability to repair gut microbiome

People with mental disorders often marry others with same

Baltimore teen accused of firing into crowd during block party mass shooting

Florida Supreme Court upholds state's abortion ban

hotspot

focus

focus

hotspot